SarcopeniaLUCAS-PENNCT05346185
Lung Cancer Surgery in Sarcopenia Patients With Old Age
An observational study of Sarcopenia and Lung Cancer, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing… Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Sarcopenia, Lung Cancer
- How many people
- 400 participants
- Where
- 1 siteSouth Korea
- Study dates
- 13 Apr 2021to 30 Jun 2028
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients above the age of 70 who are planning to undergo curative surgery for proven lung cancer or pulmonary nodules suspected for lung cancer
Who may be able to join
- Patients planning to perform curative surgery for confirmed lung cancer and pulmonary nodules suspected for lung cancer
- Patients or legal representatives who could understand and write written consent prior to the initiation of the clinical trial and are able to comply with the requirements for the clinical trial
Who cannot join
- Patients with treatment history for lung cancer or other solid cancer within 5 years (except patients with adenocarcinoma in situ for lung cancer)
- Patients who need simultaneous surgery with lung caner surgery for other accompanying diseases
- Patients who are not eligible to participate in the study judged by the researcher
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Association of Preoperative Sarcopenia on Postoperative Outcomes After Lung Cancer Surgery: Prospective Observational Study
The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing lung cancer surgery.
Read the detailed description
Sarcopenia is a syndrome characterized by a decrease in the amount and function of skeletal muscle, and is known to have a prevalence of about 6-10% in 65 years of age or older and about 20-25% in 70 years of age or older. Recently, many studies have been conducted on the clinical importance of sarcopenia, and it has been reported that sarcopenia is significantly associated with a decline in quality of life and physical activity in the elderly population, as well as harmful clinical outcomes in postoperative patients and poor long-term outcomes in various solid cancer patients. Due to the promising result of lung cancer screening trial, lung cancer has been included in national cancer screening in South Korea since last year. As a result, more people are being diagnosed with lung cancer early. Furthermore, the number of patients having surgical resection for lung cancer is steadily growing, and as life expectancy rises, even older patients are increasingly considering surgical treatment. It's critical to appropriately assess risk in older individuals before and after surgery, and sarcopenia is considered a significant fartor for major surgery. According to studies on the association between sarcopenia and the postoperative clinical outcome of lung cancer surgery, sarcopenia evaluated by computed tomography has demonstrated to be associated with a poor surgical outcome and long-term prognosis. However, according to two recognized guidelines for sarcopenia (European Working Group on Sarcopenia in Elder People, and Asian Working Group for Sarcopenia), sarcopenia is supposed to comprehensively evaluate muscle mass, muscle strength, and physical activity. Regarding muscle mass, it is recommended to measure through dual energy-ray absoptiometery or bioelectrial impedance analysis. However, so far, there are no studies that have conducted an accurate evaluation of sarcopenia in elderly lung cancer patients and analyzed the relationship between them and the clinical outcome after lung cancer surgery.
- Conditions
- Sarcopenia, Lung Cancer
- Keywords
- sarcopenia, lung cancer, surgery, long-term survival, complication, pulmonary function, quality of life
- Medical subject headings
- Sarcopenia, Lung Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
survival status during the follow-up after the lung cancer surgery
Measured: 5 years after the day of lung cancer surgery
Secondary outcomes (10)
recurrence free survival
any recurrence or death during the follow-up after the lung cancer surgery
Measured: up to 5 years after the day of lung cancer surgery
non-cancer related mortality
any death not related to lung cancer during the follow-up after the lung cancer surgery
Measured: up to 5 years after the day of lung cancer surgery
postoperative change of pulmonary function
pulmonary function during the follow-up after the lung cancer surgery
Measured: at postoperative 1 year, 5 year
postoperative complication rate
complication after lung cancer surgery
Measured: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
operative mortality
mortality related to lung cancer surgery
Measured: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
length of stays
length of hospital stays after lung cancer surgery
Measured: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
quality of life questionnaire
Five-level European quality of life Five Dimension (0 - 1, higher score means better outcome)
Measured: before the surgery, at postoperative 1 year, and at postoperative 5 year
quality of life questionnaire
European quality of life visual analogue score ( 0 - 100, higher score means a better outcome)
Measured: before the surgery, at postoperative 1 year, and at postoperative 5 year
geriatric depression scale questionnaire
Korean version geriatric depression scale (0-15, higher number indicates normal mood)
Measured: before the surgery, at postoperative 1 year, and at postoperative 5 year
cognitive function questionnaire
Korean version Montreal Cognitive Assessment
Measured: before the surgery, and at postoperative 5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2022
- Study start13 Apr 2021
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, In Kyu Park, Seoul National University Hospital
- Investigators
- In Kyu Park, MD, PhD, Principal investigator, Seoul National University Hospital, Department of Thoracic and Cardiovascular Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05346185
- Sponsor's protocol ID
- 800-20210011
- Acronym
- LUCAS-PEN
- Status last verified
- Jan 2026
- First submitted
- 20 Apr 2022
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Woo HS, Na KJ, Yun T, Park JH, Na B, Park S, Lee HJ, Kang CH, Kim YT, Park IK. Impact of sarcopenia on early surgical outcomes in elderly patients following lung cancer surgery: a prospective cohort study. J Thorac Dis. 2025 Oct 31;17(10):7838-7852. doi: 10.21037/jtd-2025-1375. Epub 2025 Oct 29.
PubMed 41229782
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Preoperative Sarcopenia on Postoperative Outcomes After Lung Cancer Surgery: Prospective Observational Study
- ClinicalTrials.gov ID
- NCT05346185
- Acronym / sponsor ID
- LUCAS-PEN / 800-20210011
- Conditions
- Sarcopenia, Lung Cancer
- Keywords
- sarcopenia, lung cancer, surgery, long-term survival, complication, pulmonary function, quality of life
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- 13 Apr 2021 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 26 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing lung cancer surgery.
Detailed description
Sarcopenia is a syndrome characterized by a decrease in the amount and function of skeletal muscle, and is known to have a prevalence of about 6-10% in 65 years of age or older and about 20-25% in 70 years of age or older. Recently, many studies have been conducted on the clinical importance of sarcopenia, and it has been reported that sarcopenia is significantly associated with a decline in quality of life and physical activity in the elderly population, as well as harmful clinical outcomes in postoperative patients and poor long-term outcomes in various solid cancer patients. Due to the promising result of lung cancer screening trial, lung cancer has been included in national cancer screening in South Korea since last year. As a result, more people are being diagnosed with lung cancer early. Furthermore, the number of patients having surgical resection for lung cancer is steadily growing, and as life expectancy rises, even older patients are increasingly considering surgical treatment. It's critical to appropriately assess risk in older individuals before and after surgery, and sarcopenia is considered a significant fartor for major surgery. According to studies on the association between sarcopenia and the postoperative clinical outcome of lung cancer surgery, sarcopenia evaluated by computed tomography has demonstrated to be associated with a poor surgical outcome and long-term prognosis. However, according to two recognized guidelines for sarcopenia (European Working Group on Sarcopenia in Elder People, and Asian Working Group for Sarcopenia), sarcopenia is supposed to comprehensively evaluate muscle mass, muscle strength, and physical activity. Regarding muscle mass, it is recommended to measure through dual energy-ray absoptiometery or bioelectrial impedance analysis. However, so far, there are no studies that have conducted an accurate evaluation of sarcopenia in elderly lung cancer patients and analyzed the relationship between them and the clinical outcome after lung cancer surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients above the age of 70 who are planning to undergo curative surgery for proven lung cancer or pulmonary nodules suspected for lung cancer
Key inclusion criteria (2 listed)
- Patients planning to perform curative surgery for confirmed lung cancer and pulmonary nodules suspected for lung cancer
- Patients or legal representatives who could understand and write written consent prior to the initiation of the clinical trial and are able to comply with the requirements for the clinical trial
Key exclusion criteria (3 listed)
- Patients with treatment history for lung cancer or other solid cancer within 5 years (except patients with adenocarcinoma in situ for lung cancer)
- Patients who need simultaneous surgery with lung caner surgery for other accompanying diseases
- Patients who are not eligible to participate in the study judged by the researcher
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival
Time frame: 5 years after the day of lung cancer surgery
survival status during the follow-up after the lung cancer surgery
10 secondary outcomes
recurrence free survival
Time frame: up to 5 years after the day of lung cancer surgery
non-cancer related mortality
Time frame: up to 5 years after the day of lung cancer surgery
postoperative change of pulmonary function
Time frame: at postoperative 1 year, 5 year
postoperative complication rate
Time frame: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
operative mortality
Time frame: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
length of stays
Time frame: from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)
quality of life questionnaire
Time frame: before the surgery, at postoperative 1 year, and at postoperative 5 year
quality of life questionnaire
Time frame: before the surgery, at postoperative 1 year, and at postoperative 5 year
geriatric depression scale questionnaire
Time frame: before the surgery, at postoperative 1 year, and at postoperative 5 year
cognitive function questionnaire
Time frame: before the surgery, and at postoperative 5 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
- Derived from this study: PubMed 41229782Woo HS, Na KJ, Yun T, Park JH, Na B, Park S, Lee HJ, Kang CH, Kim YT, Park IK. Impact of sarcopenia on early surgical outcomes in elderly patients following lung cancer surgery: a prospective cohort study. J Thorac Dis. 2025 Oct 31;17(10):7838-7852. doi: 10.21037/jtd-2025-1375. Epub 2025 Oct 29.
- Individual participant dataSharing planned: Undecided
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
In Kyu Park, MD, PhD principal investigator
Seoul National University Hospital, Department of Thoracic and Cardiovascular Surgery
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia and Lung Cancer, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: 5 years after the day of lung cancer surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05346185, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.